Avanos Medical appoints Dr. Lisa Egbuonu-Davis to board of directors

AVANOS MEDICAL, INC.

Dr. Egbuonu-Davis appointed as independent director effective March 6, 2023; serves on Compliance and Governance Committees.
She receives $70,000 annual cash retainer, $7,500 Compliance Committee fee, $5,000 Governance Committee fee, and $190,000 in RSUs.
Board now comprises six directors: five independent, two women, one ethnically diverse.
Egbuonu-Davis is VP Medical Innovations at DH Diagnostics (Danaher affiliate); previously VP at Sanofi and roles at Pfizer.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Lisa Egbuonu-Davis

Director

AVNS · AVANOS MEDICAL, INC.

Effective: 2023-03-06
Filed: March 6, 2023, 6:59 PM ET

On February 28, 2023, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Dr. Lisa Egbuonu-Davis to the Board, effective March 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Lisa Egbuonu-Davis was appointed as Director at AVANOS MEDICAL, INC..

Action: appointed
Role: Director

Exact text from the filing

On February 28, 2023, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Dr. Lisa Egbuonu-Davis to the Board, effective March 6, 2023.

View on SEC.gov

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.